Physician profile
Clarence E Coker
NPI 1003891508
$3,971.13
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,957 · 2020: $327 · 2021: $205 · 2022: $1,158 · 2023: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $324.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $512.66 | 2019-2023 | Breztri, Farxiga |
| Novo Nordisk INC | $315.83 | 2019-2023 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.78 | 2019-2022 | |
| Lilly USA, LLC | $237.45 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $226.63 | 2019-2023 | |
| Abbott Laboratories | $201.80 | 2019-2023 | Freestyle Libre 3 |
| Baxter Healthcare | $192.62 | 2022 | |
| Amgen INC. | $162.84 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $154.64 | 2019-2023 | Strensiq |
| Takeda Pharmaceuticals U.S.A., INC. | $147.87 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $127.19 | 2019 | |
| Jazz Pharmaceuticals INC. | $127.05 | 2019-2022 | |
| Abbvie INC. | $123.21 | 2019-2023 | Vraylar |
| Sanofi-Aventis U.S. LLC | $120.19 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.35 | 2019-2023 | Xifaxan, Trulance |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clarence Coker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.